Columnar Cell Variant Thyroid Gland Papillary Carcinoma clinical trials at UC Health
1 in progress, 0 open to new patients
Pembrolizumab and Lenvatinib in Treating Metastatic or Recurrent Differentiated Thyroid Cancer That Cannot Be Removed by Surgery
Sorry, not yet accepting patients
This phase II trial studies how well pembrolizumab and lenvatinib work in treating patients with differentiated thyroid cancer that has spread to other places in the body or has come back and cannot be removed by surgery. Monoclonal antibodies, such as pembrolizumab and kinase inhibitors, such as lenvatinib, may interfere with the ability of tumor cells to grow and spread.